It is not intended for human consumption, therapeutic, or diagnostic use
Of note, in normal cells, persistent activation of NRF2 due to functional defects of KEAP1-mediated NRF2 degradation is sometimes deleterious, while transient activation of NRF2 in response to various stimuli can be beneficial for our health
Certificate of Analysis Available (where applicable)
Clinical trials are still needed to validate their safety and efficacy in human patients before they can be widely used in AD therapy
In fact, KLOW often works best when its part of a comprehensive care plan
The throughline of the Huberman Lab episode is that safety and efficacy work together: the right compound, at the right dose, for the right patient, managed over time